Etanercept was FDA approved for use in pediatric psoriasis (PsO) in 2016 and ustekinumab was similarly approved in 2020. This comparative analysis looks at the risk of serious infections (SIE) requiring hospitalization in pediatric PSO patients treated with ustekinumab, etanercept, or methotrexate prior to 2016.
Dr. John Cush RheumNow
3 years 7 months ago
ChatGPT - A Boom or Threat to Scientific Publication?
ChatGPT is a new, AI chatbot that has dramatically changed the digital worlds of education, research, statistics and more.
Recently there were reports of ChatGPT passing the LSAT, USMLE, and more.
https://t.co/CZd0WjOas5 https://t.co/Nx49SqXoHG
Dr. John Cush RheumNow
3 years 7 months ago
High- Versus Low-Dose Exercise Therapy for Knee Osteoarthritis
The Annals of Internal medicine has reported the results of high-dose versus low-dose exercise therapy demonstrating no benefits from more intense exercise.
https://t.co/BtqeYWKG34 https://t.co/ngyM1DshDz
Dr. John Cush RheumNow
3 years 7 months ago
Multicenter study of 80 AOSD & 60 controls used to develop AOSD criteria:
- 3 pts rash
- 3pts fever ≥ 39C
- 2 pts pharyngitis
- 2 pts arthritis
- 2 pts NLR ≥ 4
- 1 pt glycosyl ferritin ≤ 20%
7 pts = Dx (sens 92.5%) vs Yamaguchi(79%), Fautrel (76%) https://t.co/Amew1RHaA1 https://t.co/dnJ6zVyfOW
Dr. John Cush RheumNow
3 years 7 months ago
Full read, solid review of Diagnosis and management of autoimmune hepatitis from BMJ https://t.co/9OdxHjXMKW https://t.co/1kuHPZBLSE
Dr. John Cush RheumNow
3 years 7 months ago
Pregnancy & RA: metanalysis of 9 studies, 12K RA pts met vs 10 million controls. RA preg have more maternal complications (C sect OR 1.55; preeclampsia OR, 1.6; preterm OR, 1.8) & neonatal probs (low gestat wt, ICU OR 1.34, & stillbirths OR, 1.99). https://t.co/30WTMC3MKn https://t.co/VXoHesd3iT
Dr. John Cush RheumNow
3 years 7 months ago
Univ of Toronto’s PsA Study looked at surgery amongst 1574 pts: 185 pts (~12%) had 379 MSK surgeries related to PsA. Signif higher rates of surgery were seen w/ #damaged joints (HR 1.03), TJC/SJC (HR 1.04), nail Dz (2.08), ^ ESR (2.37), B27+ (2.22) https://t.co/XdUJ0guwUh
Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said.
Dr. John Cush RheumNow
3 years 7 months ago
Frailty in Vasculitis
Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on at the ACR22 Convergence.
https://t.co/u0CZuEcyM9 https://t.co/JXEcSoHsA2
Dr. John Cush RheumNow
3 years 7 months ago
New Guideline: Vaccinations OK With Few Tweaks for Rheum Patients
Nearly all available vaccines can be given to people with rheumatologic diseases, according to a new, detailed guideline from the ACR.
https://t.co/514mIylgzj https://t.co/9Zq9pGcujV
Dr. John Cush RheumNow
3 years 7 months ago
Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/TampvCiCIs https://t.co/y9FDVJoEaD
Dr. John Cush RheumNow
3 years 7 months ago
Metanalysis of Steroid Tx & metabolic events (118 studies & 17113 pts) showed an increased risk:
- hyperglycemia 10% (esp lung dz 22%)
- severe hyperglyc. 5%, HTN 6%, Wt gain 13% , hyperlipid 8%
- Incr risk of hyperglyc(OR 2), HTN (1.7), Wt gain (5.2) https://t.co/E54IB3YVfn https://t.co/CPzrgIgJ12
Dr. John Cush RheumNow
3 years 7 months ago
Full read, very good review of steroids, HPA suppression, equivalents, use during surgery etc from J Endo Society. Notably literature supports continued daily GC in surgical patients, with a short course of perioperative IV GC https://t.co/jzNE5o0DBG https://t.co/6V8mhTOVTv
Dr. John Cush RheumNow
3 years 7 months ago
About 1 mo ago we reported US drug makers would increase price of 350 drugs; now it seems US Pharma has raised list prices of 983 arthritis, cancer and otherdrugs by an average of 5.6% in Jan 2023; as industry faces new federal laws to control costs https://t.co/HkdDurbNrQ https://t.co/rEvmwACdfk
GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
